Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11090278 | NEXUS PHARMS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(16 years from now) | |
US11241400 | NEXUS PHARMS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(16 years from now) | |
US11464752 | NEXUS PHARMS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(16 years from now) | |
US11478436 | NEXUS PHARMS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(16 years from now) | |
US11571398 | NEXUS PHARMS | NA |
May, 2040
(16 years from now) |
Drugs and Companies using EPHEDRINE SULFATE ingredient
Market Authorisation Date: 17 April, 2020
Treatment: Use of ephedrine sulfate for treating hypotension
Dosage: SOLUTION;INTRAVENOUS
7
United States
1
Korea, Republic of
1
China
1
Israel
1
Canada
1
Japan
1
Australia
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic